Lilian Parillo MD

Medico Gastroenterología. Endoscopia digestiva. Screening save lives!! colon cancer screening #NASH #OBESITY #IBS #helicobacter

[EASL Education @EASLedu]

⏬Download the Best of #EASLCongress Slide Decks on #EASLCampus!

These editable Slide Decks bring together the top selected abstracts from the Congress in each topic track. 📚

🔗https://t.co/5h8kEIvrnA

@EASLNews @CornbergMarkus @JasmohanBajaj @hlcortezpinto @Alexfornergon @horstef @SilviaAffo

#LiverX #BestOf

[Lilian Parillo MD @li_pd]

@invierte_joven Gastos

[Lilian Parillo MD @li_pd]

@Ai_here202 All

[Scott Isaacs @scottisaacsmd]

Must-read Review in Nature Medicine from @DanielJDrucker: a masterclass on how GLP-1 medicines moved from glucose control to reshaping obesity, CV, liver, kidney, neuro and addiction care.
https://t.co/8ydiYIxdS0

[Lilian Parillo MD @li_pd]

@lisaknowsai Claude

[Scott Isaacs @scottisaacsmd]

Estradiol fluctuations across the life course shape #MASLD risk, with risk rising once estrogen levels fall after #menopause.
@EndoSocJournals
https://t.co/oreNGGxaIA

[Eric Topol @EricTopol]

The gastrointestinal side effects of GLP-1 drugs are mediated by the brain, not the gut. The gut-brain axis at work @jclinicalinvest
https://t.co/8meow41j83

[Dr. Filippo Cademartiri @FCademartiri]

🪨🫀 Seventeen years to change practice: will the 2025 ESC/EAS lipid guidelines finally move the needle?

This 2026 Atherosclerosis state-of-the-art review by Ray & Kronenberg asks a blunt question many clinicians quietly share: why does it take nearly two decades for lipid guidelines to meaningfully change real-world care—and will 2025 be different?

🧠 What’s genuinely new in 2025
The update modernizes lipid care in important ways:
📊 SCORE2 & SCORE2-OP now include fatal + non-fatal events and extend risk prediction up to age 89, correcting long-standing underestimation in women and younger adults
🧪 Non–HDL-C replaces total cholesterol, a biologically smarter move
💊 Expanded therapies: bempedoic acid, evinacumab, clearer positioning of icosapent ethyl
🚑 Acute coronary syndrome care flips the script: early, upfront combination therapy instead of slow stepwise escalation
🧬 Universal Lp(a) testing once in adulthood—finally explicit, finally serious

⚠️ But the Sisyphean problem remains
The authors are unsparing about what still holds us back:
Guidelines assume monotherapy first, despite clear evidence that 50–80% of high-risk patients need combination therapy from day one
Persistent inconsistencies across ESC documents (prevention, diabetes, dyslipidaemia)
Risk thresholds remain arbitrary, short-term, and poorly aligned with lifetime risk
Above all: implementation failure—evidence moves fast, practice crawls

🧠 The real insight
This is not a science problem.
It’s an implementation science failure.

Publishing better guidelines without embedding behavioral change, digital tools, feedback loops, and system-level incentives simply restarts the 17-year cycle.

🔮 Bottom line
The 2025 ESC/EAS update is scientifically stronger, more modern, and more honest than its predecessors.
But unless guidelines are designed for how clinicians actually work, the rock will keep rolling back downhill.

👉 The question is no longer what we recommend.
🧭 It’s how we make it happen—this time faster than 17 years.

[Elliot Tapper @ebtapper]

GLP crushes MASH: systematic review

https://t.co/X1gRxRcvj7 @HepCommJournal @SighPichamol

[Eric Topol @EricTopol]

A 5★ new review of the GLP-1 drugs, what they have achieved, and where the field is headed with so many new molecules and combinations @TheLancet
https://t.co/E1Xa15fk1q

[Scott Isaacs @scottisaacsmd]

Extrahepatic manifestations of #MASLD.
https://t.co/8XoDaHRLeB

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Our #MostRead article in 2025:
Definition and diagnostic criteria of #clinical #obesity https://t.co/cM8pyJ2UG9
#FREE to read with registration (also FREE)

[GeniusThinking @GeniusGTX]

I'm obsessed with cognitive biases.

A "cognitive bias" is a systematic error in thinking that destroys decision-making.

11 most powerful (and dangerous) cognitive biases I've found: 🧵

1. Survivorship Bias:

[Achintya Singh, MD @AchintyaSinghMD]

Excellent illustrations, review of pancreas cysts: https://t.co/pUTGtfByS3
➡️ 15% panc cancer arise from cysts
➡️ EUS>MRI: connection with ducts, ampulla evaluation, mural nodules
➡️VHL: Serous, MEN: NET, KRAS or GNAS: IPMN, GTNNB1: SPNT
➡️Minimal surgical excision is an option!

[John Damianos, M.D. @john_damianosMD]

The gut microbiome can contribute to systemic inflammation by activation of inflammasomes

[Jan Král @KralJan]

#Obesity is more than lifestyle 🍔

👉 https://t.co/Q46E98lKNY

❗️ This review links Social Determinants of Health (SDOH) 🏘️🧠(e.g. stress, poverty) to brain–gut–microbiome (BGM) disruption and eating behaviors.

#GITwitter #MedTwitter #Microbiome #MedEd @AGA_CGH @AmerGastroAssn

[Science News @SciencNews]

Eleven clinical trials that will shape medicine in 2026

[Scott Isaacs @scottisaacsmd]

New review frames insulin resistance as the crossroads of metabolic inflammation, MASLD/MASH, CVD, organ failure & cancer. Simply “fixing IR” is necessary but not sufficient once the dysmetabolic fire is lit.
https://t.co/XFiMM7zMEL

[Eric Topol @EricTopol]

The one validated intervention to slow aging and extend healthspan is not for sale.
It's exercise.
https://t.co/3ezUq8QvKe

[ESGE @ESGE_news]

🚨This week's #WednesdayWebinar – Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): Case-based highlights

📆 Wed, Dec 3, 19:00 CET

🔗https://t.co/Cymhr9qTAN

Explore Clinical cases that illustrate key concepts & practical approaches